208 related articles for article (PubMed ID: 33816318)
1. Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis.
Long Z; Huang M; Liu K; Li M; Li J; Zhang H; Wang Z; Lu Y
Front Oncol; 2021; 11():662318. PubMed ID: 33816318
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients.
Yao H; Chen X; Tan X
BMC Cancer; 2021 Apr; 21(1):449. PubMed ID: 33892656
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study.
Wang X; Wang J; Sun B; Sun Y; Liu N; Niu X; Li C; Li L; Zhang Q; Hao J; Wang X
Ann Transl Med; 2022 Sep; 10(18):961. PubMed ID: 36267758
[TBL] [Abstract][Full Text] [Related]
4. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
[No Abstract] [Full Text] [Related]
5. Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients.
Huang D; He Q; Zhai L; Shen J; Jing F; Chen H; Zhu X; Zhou J
Front Pharmacol; 2022; 13():843905. PubMed ID: 36034824
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.
Liu X; Xu J; Li F; Liao Z; Ren Z; Zhu L; Shi Y; Zhao G; Bai X; Zhao J; Xing R; Teng S; Yang Y; Yang J
Biomed Pharmacother; 2020 Feb; 122():109587. PubMed ID: 31786466
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients.
Weitao Y; Fangxing W; Qiqing C; Jiaqiang W
Anticancer Drugs; 2019 Aug; 30(7):e0778. PubMed ID: 31305297
[TBL] [Abstract][Full Text] [Related]
8. Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer.
Liu H; Li Y; Yao Y; Chen K; Gan J
Dis Markers; 2022; 2022():6971717. PubMed ID: 36193493
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of safety and efficacy of apatinib combination with chemotherapy for ovarian cancer treatment: a systematic review and meta-analysis.
Qi J; Liu E; Yue H; Chen G; Liu Y; Chen J
Ann Palliat Med; 2021 Sep; 10(9):9902-9913. PubMed ID: 34551570
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China.
Li F; Liao Z; Zhao J; Zhao G; Li X; Du X; Yang Y; Yang J
Oncotarget; 2017 Sep; 8(38):64471-64480. PubMed ID: 28969086
[TBL] [Abstract][Full Text] [Related]
11. [Clinical efficacy and safety of apatinib combined with chemotherapy for osteosarcoma and soft tissue sarcoma with pulmonary metastasis].
Li SL; Yang QK; Chen P; Zheng K; Wang W; Pei Y; Zhang XJ
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):309-314. PubMed ID: 31014058
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis.
Peng D; Cai Y; Chen G; Hou M; Luo X; Dongzhi Z; Xie H; Liu Y
Front Pharmacol; 2023; 14():1101063. PubMed ID: 37153777
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis.
Huang X; Hu X; Yi T
Front Oncol; 2022; 12():940171. PubMed ID: 35978823
[TBL] [Abstract][Full Text] [Related]
14. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.
Tian Z; Liu H; Zhang F; Li L; Du X; Li C; Yang J; Wang J
Invest New Drugs; 2020 Oct; 38(5):1559-1569. PubMed ID: 32100146
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.
Lin H; Weng X; Wu X; Wu L
Transl Cancer Res; 2022 Jun; 11(6):1770-1780. PubMed ID: 35836539
[TBL] [Abstract][Full Text] [Related]
16. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of apatinib plus chemotherapy vs. chemotherapy alone for the treatment of advanced‑stage non‑small cell lung cancer: A meta‑analysis.
Qin S; Han X; Li Z
Oncol Lett; 2024 Jan; 27(1):25. PubMed ID: 38073772
[TBL] [Abstract][Full Text] [Related]
18. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
19. A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis.
Zhao S; Zhang T; Dou W; Wang E; Wang M; Wang C; Du X; Liu L
Ann Transl Med; 2020 Apr; 8(8):542. PubMed ID: 32411765
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis.
Sun D; Hou H; Zhang C; Zhang X
Onco Targets Ther; 2018; 11():6539-6554. PubMed ID: 30323627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
